Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY: BLCO )

15.35 +0.16 (+1.05%)
Official Closing Price Updated: 6:30 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 Next >
Medical Devices & Supplies - Specialty Stocks Q4 In Review: Globus Medical (NYSE:GMED) Vs Peers
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers. 
Via StockStory
3 Stocks Under $50 Walking a Fine Line
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises
The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China. 
Via Stocktwits
Topics Earnings
Exposures Financial
Globus Medical (GMED) Q4 Earnings: What To Expect
Medical device company Globus Medical (NYSE:GMED) will be announcing earnings results tomorrow after the bell. Here’s what to expect. 
Via StockStory
Earnings Scheduled For February 19, 2025
Via Benzinga
Why Bausch + Lomb Rallied Today
The highly indebted healthcare stock rose on rumors it may be selling itself. 
Via The Motley Fool
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Earnings To Watch: Integer Holdings (ITGR) Reports Q4 Results Tomorrow
Medical technology company Integer Holdings (NYSE:ITGR) will be announcing earnings results tomorrow before market hours. Here’s what you need to know. 
Via StockStory
Bausch + Lomb’s (NYSE:BLCO) Q4: Beats On Revenue
Eyecare company Bausch + Lomb (NYSE:BLCO) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 9.1% year on year to $1.28 billion. On the other hand, the company’s full-year... 
Via StockStory
Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect
Eyecare company Bausch + Lomb (NYSE:BLCO) will be announcing earnings results tomorrow morning. Here’s what to expect. 
Via StockStory
Deal Dispatch: PharmChem Forgoes Banker To Run Sale, TGI Fridays Sells 19 Restaurants For $3.1 Million
Bausch + Lomb's efforts to sell have so far been unsuccessful. Meanwhile, KKR is aggressively pursuing a deal for Fuji Soft. 
Via Benzinga
Aehr Test Systems Posts Weak Results, Joins Trump Media & Technology Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Topics Government
Exposures Political
Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Deal Dispatch: Ubisoft In Buyout Talks, Dental Supplier Explores Sale, Beloved Drive-Through Goes Bankrupt
Dental supply maker Patterson Companies Inc announced Thursday that it is exploring strategic options, including a sale or merger, to boost shareholder value. 
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
Deal Dispatch: UFC, WWE Parent TKO Takes On Bull Riding; Endeavor Looks To Sell Tennis; Another Car Company Goes Bankrupt
IMG tennis assets are on the auction block. The announcement came after TKO inked a deal with Endeavor for Professional Bull Riders. 
Via Benzinga
Deal Dispatch: Altus Power, Motorsport Games Explore Options, True Value Goes Bankrupt, M&A Activity Lags
S&P Global's Joe Mantone puts the latest M&A data in perspective and how deal pros might react post-Election Day. 
Via Benzinga
Topics Bankruptcy Stocks
Exposures Financial Legal US Equities
This Advance Auto Parts Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Why Bausch + Lomb Stock Soared by Over 7% on Monday
It was quite a busy and eventful day for the company. 
Via The Motley Fool
NVIDIA, Trump Media & Technology, Bausch + Lomb, Sirius XM And Other Big Stocks Moving Higher On Monday
Via Benzinga
Topics Government
Exposures Political
Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
Private equity giants TPG and Blackstone are pursuing a potential $14 billion buyout of Bausch + Lomb. 
Via Benzinga
Nike Reports Weak Sales, Joins Lamb Weston And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Contact Lens Supplier Bausch + Lomb Eyes Sale Amid Separation Challenges As Parent Bausch Health Faces Debt Issues
Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a spin-off. 
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?
Bausch + Lomb is reportedly considering a sale. But its potential acquirers could come up against antitrust concerns. 
Via Investor's Business Daily
Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why Is Clearside Biomedical Stock Gaining Today?
Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS... 
Via Benzinga
Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday?
Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Committee (FOMC) meeting. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Wall Street Remains On Track For AMD-Led Rebound Ahead Of Fed Decision, Meta Earnings: Analyst Says 'The Bull Tends To Remain' Despite Near-Time Volatility
Tech optimism is likely to abound on Wall Street as AI-levered stocks are feeding off the strength generated by Advanced Micro Devices, Inc.‘s (NASDAQ:AMD) 
Via Benzinga
Topics Economy
Exposures Interest Rates
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.